3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
5
Recruiting
3
Unknown
1
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
6
Thymoma
1
Neoplasm Metastasis
1
Esophageal Neoplasms
1
Clinical Stage III Gastric Cancer AJCC v8
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Gastric Cancer
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Docetaxel
5
Pemetrexed
4
Capecitabine
4
pembrolizumab
3
Oxaliplatin
3
icotinib
2
Radiation
2
Paclitaxel
2
Gemcitabine
2
Gefitinib
2
Fluorouracil
2
Drug Therapy
2
Chemoradiotherapy
2
Carboplatin
2
sintilimab
1
rucaparib
1
regorafenib
1
olaparib
1
lenvatinib
1
iron isomaltoside 1000
1
ipatasertib
1
iopromide
1
gluconic acid
1
elemene
1
capecitabine-irinotecan combination
1
aumolertinib
1
atezolizumab
1
anlotinib
1
aflutinib
1
XELOX
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Adenocarcinoma
×
Ramucirumab
×
Clear all
NCT03995017
2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2
Unknown
34 enrolled